Save information for later
Sign Up

Learn About Olivopontocerebellar Atrophy

What is the definition of Olivopontocerebellar Atrophy?
Olivopontocerebellar atrophy (OPCA) is a term used for a progressive condition characterized by the degeneration of nerve cells (neurons) in specific areas of the brain. OPCA can be viewed as a finding of several diseases, and indicates a form of progressive ataxia (abnormal or uncontrolled movements) distinguished by characteristic findings in brain imaging studies and at autopsy (pontine flattening and cerebellar atrophy). It was traditionally divided in hereditary or genetic OPCA and sporadic OPCA. Currently, most of the major forms of hereditary OPCA refer to disorders that overlap with spinocerebellar ataxia (SCA), which is a neurological disorder characterized by ataxia. The sporadic forms are considered now to be a form of multiple system atrophy (MSA). OPCA may also occur in people with prion disorders and inherited metabolic diseases. The main symptom is clumsiness that slowly gets worse. Other symptoms may include problems with balance; speech or swallowing problems; difficulty walking; abnormal eye movements; muscle spasms; and neuropathy. Whether OPCA is inherited (and the inheritance pattern) depends on the underlying cause, if known.
What are the alternative names for Olivopontocerebellar Atrophy?
  • Olivopontocerebellar atrophy
  • OPCA
Who are the top Olivopontocerebellar Atrophy Local Doctors?
Puneet Opal
Elite in Olivopontocerebellar Atrophy
Neurology
Elite in Olivopontocerebellar Atrophy
Neurology
259 E Erie St Ste 1900, Lavin Family Pavilion, 
Chicago, IL 
Experience:
36+ years
Languages Spoken:
English

Puneet Opal is a Neurologist in Chicago, Illinois. Dr. Opal has been practicing medicine for over 36 years and is rated as an Elite provider by MediFind in the treatment of Olivopontocerebellar Atrophy. His top areas of expertise are Spinocerebellar Ataxia Type 1, Giant Axonal Neuropathy, Olivopontocerebellar Atrophy, and Spinocerebellar Ataxia.

Elite in Olivopontocerebellar Atrophy
Elite in Olivopontocerebellar Atrophy
1600 Sw Archer Rd, 
Gainesville, FL 
Languages Spoken:
English
Accepting New Patients

Tetsuo Ashizawa is a Neurologist in Gainesville, Florida. Dr. Ashizawa is rated as an Elite provider by MediFind in the treatment of Olivopontocerebellar Atrophy. His top areas of expertise are Olivopontocerebellar Atrophy, Spinocerebellar Ataxia, Spinocerebellar Ataxia Type 10, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Ashizawa is currently accepting new patients in some locations.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Olivopontocerebellar Atrophy
Elite in Olivopontocerebellar Atrophy

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Jeremy Schmahmann is a Neurologist in Boston, Massachusetts. Dr. Schmahmann is rated as an Elite provider by MediFind in the treatment of Olivopontocerebellar Atrophy. His top areas of expertise are Spinocerebellar Ataxia, Acute Cerebellar Ataxia, Olivopontocerebellar Atrophy, Drug Induced Dyskinesia, and Gastrostomy. Dr. Schmahmann is currently accepting new patients.

What are the latest Olivopontocerebellar Atrophy Clinical Trials?
Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

Summary: The purpose of this study is to create a repository for cerebellar ataxia and nucleotide repeat diseases in order to fully investigate the genetic and phenotypic presentations of both.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to c...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center